Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes

Diabetes

Volumn 45, Issue 1, 1996, Pages 91-100

  Moses, Alan C ^a,c   Young, Simon C J ^b   Morrow, Linda A ^a   O'Brien, Maureen ^a   Clemmons, David R ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN; INSULIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY COMPOSITION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030032795     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.1.91     Document Type: Article

References (37)

1. Kolaczynski JW, Caro JF: Insulin-like growth factor-I therapy in diabetes: physiological basis, clinical benefits, and risks. Ann Int Med 120:47-55, 1994
2. Zeuobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER: Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes J Clin Invest 90:2234-2241, 1992
3. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 92:2249-2256, 1993
4. Schalch DS, Turman NJ, Marcsism VS, Heffernan M, Guler H-P: Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes J Clin Endocrinol Metab 77:1563-1568, 1993
5. Rossetti L, Frontoni S, Dimarchi R, DeFronzo RA, Giaccari A: Metabolic effects of IGF-I m diabetic rats. Diabetes 40:444-448, 1991
6. Rechler MM, Zapf J, Nissley SP, Froesch ER, Moses AC, Podskalny JM, Schilling EE, Humbel RE: Interactions of insulin-like growth factors I and II and multiplication stimulating activity with receptors and serum carrier proteins. Endocrinology 107:1451-1459, 1980
7. Gulcr H-P, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317:137-140, 1987
8. Elahi D, McAloon-Dyke M, Fukagawa NK, Sclater AL, Wong GA, Shannon RP, Minaker KL, Miles JM, Rubenstein AH, Vanderpol CJ, Guler HP, Good WR, Seaman JJ, Wolfe RR: Effects of recombinant human IGF-I on glucose and leucine kinetics in men Am J Physiol 265:E831-E838, 1993
9. Bilan PJ, Ramlal T, Klip A: IGF-I mediated recruitment of glucose transporters from intracellular membranes to plasma membranes in L6 muscle cells. Adv Exp Med Biol 293:273-288, 1991
10. Poggi C, LeMarchand-Brustal Y, Zapf J, Froesch ER, Freychet P: Effects of and binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: comparison with insulin. Endocrinology 105: 723-730, 1979
11. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler H-P: Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 43:369-374, 1994
12. Schoenle EJ, Zenobi PD, Toresarie T, Wender EA, Zachman M, Froesch ER: Recombinant insulin like growth factor 1 (rhIGF-I) reduces hyperglycemia in patients with insulin resistance. Diabetologia 34:675-679, 1990
13. Quin JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, MacCuish AC: Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome. N Engl J Med 323:1425-1426, 1990
14. Usala A-L, Madigan TI, Burguera B, Sinha MK, Caro JF, Cunningham P, PoWell JG, Butler PC: Brief report: treatment of insulin resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin dependent diabetes. N Engl J Med 327:853-857, 1992
15. Hussain MA, Froesch RR: Treatment of type A insulin resistance with insulin-like growth factor I. Lancet 341:1536-1537, 1993
16. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER: Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 92-2249-2256, 1993
17. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC: Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 79:205-210, 1994
18. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y, Kobayashi M, Akazawa Y, Nomura M, Yoshmasa Y, Kasuga M, Goji K, Nagataki S, Oyasu H, Imura H: Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42:696-705, 1993
19. Bergman RN, Finegold DT, Ader M: Assessment of insulin sensitivity in vivo. Endocr Rev 6:45-86, 1985
20. Welch S, Gebhart SSP, Bergman RN, Phillips LS: Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508-1518, 1990
21. Davenport M, Svoboda ME, Koerber KL, Van Wyk JJ, Clemmons DR, Underwood LE: Plasma concentrations of insulin like growth factor II (IGF-II) are not changed by short term fasting and refeeding. J Clin Endocrinol Metab 67:1231-1236, 1980
22. Voina SJ, Underwood LE, Van Wyk JJ: Failure of leucine, arginine, and epinephrine to alter plasma Insulin levels in vitro, Horm Metab Res 3:127-128, 1971
23. Busby WH, Snyder DK, Clemmons DR. Radioimmunoassay of a 26,000 dalton plasma insulin like growth factor binding protein: control by nutritional variables. J Clin Endocrinol Metab 67:1225-1230, 1988
24. Clemmons DR, Busby WH, Snyder DK: Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 73:727-733, 1991
25. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Bebarski SS, Kelch RP, Beitins IZ. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201 995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate, J Clin Endocrinol Metab 67:1040-1048, 1988
26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes. N Engl J Med 329:977-086, 1993
27. Merchav S, Tatarsky I, Hochberg Z: Enchancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor I/somatomedin C and human growth hormone. J Clin Invest 81:791-795, 1988
28. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS: Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin: dose-response relationships in healthy young and middle-aged adults. J Clin Invest 93:1131-1139, 1994
29. McAloon-Dyke M, Kukagawa NK, Minaker KL, Guler H-P, Wolfe RR, Elahi D: The effects of insulin-like growth factor-I on leucine and glucose kinetics in type II diabetes (Abstract). Clin Research 42:118A, 1994
30. Dohm GL, Elton CW, Raju MS, Mooney ND, DiMarchi R, Pories WJ, Flickinger EG, Atkinson SM Jr, Caro JF: IGF-I stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes 39:1028-1032, 1990
31. Jacob RJ, Sherwin RS, Greenawalt K, Shulman GI: Simultaneous insulin-like growth factor I and insulin resistance in obese Zucker rats. Diabetes 41:691-697, 1992
32. Hartman ML, Clayton PE, Johnson ML, Celniker A, Perlman AJ, Alberti KG, Thorner MO: A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J Clin Invest 91:2453-2462, 1993
33. Skolnik EY, Lee CH, Batzer A. Vicentini LM, Zhou M, Daly R, Myers MJ Jr, Backer JM, Ullrich A, White MF, Schlessinger J: The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRSI and Shc: implications for insulin control of ras signalling. EMBO J 12:1929-1936, 1993
34. Myers MG, Sun XJ, Cheatham B, Jachna BR, Glasheen EM, Bacher JM, White MF: IRS-l is a common element in insulin and insulin-like growth factor I signalling to the phosphatidylinositol 5'-kinase. Endocrinology 132:1421-1430. 1993
35. Moxham CP, Duronio V, Jacobs S: Insulin-like growth factor I receptor ß-subunit heterogeneity: evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 264:13238-13244, 1989
36. Condorelli G, Bueno R, Smith RJ: Two alternatively spliced forms of the human insulin-like growth factor I receptor have distinct biological activities and internalizarion kinetics J Biol Chem 209: 8510-8516, 1994
37. Wilton P: Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome): Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Ada Paediatr Suppl 383:137-142, 1992